secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001104659-26-008410
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix gets positive CHMP opinion for every-4-week dosing of Elfabrio in EU; $25M milestone if EC approves
--------------------------------------------------------------------------------

- CHMP issued positive opinion for 2 mg/kg every-4-weeks dosing regimen of Elfabrio for stable Fabry adults.
- Positive opinion follows re-examination; EC decision expected by March 2026.
- Protalix eligible for $25M regulatory milestone from Chiesi if EC approves the regimen.
- The extended dosing interval aims to reduce treatment burden; regimen not approved in U.S.
- BRIGHT study and ongoing extension with median exposure ~6 years supported the opinion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926008410/0001104659-26-008410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926008410/tm264565d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer